🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise around the world, with estimates suggesting over 82 million new cases annually. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Ongoing monitoring found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This approval represents a major breakthrough in the therapy of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Outcomes and Global Access

According to results published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which combines two antibiotics. The research involved over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the authority to make available and distribute the drug in a wide range of developing nations.

Medical professionals treating patients have voiced positive views. Having a single-dose, oral treatment like this is described as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.